657 related articles for article (PubMed ID: 20061694)
1. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk assessment and homocysteine and leptin levels in peritoneal dialysis and hemodialysis patients.
Bekpinar S; Unlüçerçi Y; Genç S; Türkmen A
Adv Perit Dial; 2005; 21():80-4. PubMed ID: 16686291
[TBL] [Abstract][Full Text] [Related]
3. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.
Samouilidou EC; Grapsa E
Ren Fail; 2008; 30(7):711-5. PubMed ID: 18704820
[TBL] [Abstract][Full Text] [Related]
4. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
5. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
[TBL] [Abstract][Full Text] [Related]
6. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
[TBL] [Abstract][Full Text] [Related]
7. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients.
Yang WS; Kim SB; Min WK; Park S; Lee MS; Park JS
Nephrol Dial Transplant; 1995; 10(9):1668-71. PubMed ID: 8559487
[TBL] [Abstract][Full Text] [Related]
9. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ
J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756
[TBL] [Abstract][Full Text] [Related]
10. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
[TBL] [Abstract][Full Text] [Related]
11. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
12. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
[TBL] [Abstract][Full Text] [Related]
13. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
14. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels.
Borazan A; Aydemir S; Sert M; Yilmaz A
Mediators Inflamm; 2004 Dec; 13(5-6):361-4. PubMed ID: 15770053
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.
Bossola M; Giungi S; Panocchia N; Vulpio C; Luciani G; Tazza L
J Nephrol; 2008; 21(2):197-204. PubMed ID: 18446714
[TBL] [Abstract][Full Text] [Related]
16. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
Arikan H; Koc M; Sari H; Tuglular S; Ozener C; Akoglu E
Ren Fail; 2007; 29(6):713-9. PubMed ID: 17763167
[TBL] [Abstract][Full Text] [Related]
17. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
[TBL] [Abstract][Full Text] [Related]
18. [Dyslipidemia in patients being treated with peritoneal dialysis].
Zharfbin A
Vnitr Lek; 2006 Nov; 52(11):1051-7. PubMed ID: 17165524
[TBL] [Abstract][Full Text] [Related]
19. Malnutrition, inflammation, and lipids in a cohort of dialysis patients.
Bowden RG; Wilson RL
Postgrad Med; 2010 May; 122(3):196-202. PubMed ID: 20463430
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for vascular complications in patients on peritoneal dialysis.
Arima H; Nakamoto H; Okada S; Inoue T; Kobayashi K; Shoda J; Ikeda N; Kanno Y; Sugahara S; Okada H; Suzuki H
Adv Perit Dial; 2006; 22():192-7. PubMed ID: 16983968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
